

IRADIMED CORP  
Form 8-K  
June 11, 2018

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT**  
**TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): **June 8, 2018**

**IRADIMED CORPORATION**

(Exact Name of Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**001-36534**  
(Commission File Number)

**73-1408526**  
(IRS Employer Identification No.)

**1025 Willa Springs Dr., Winter Springs, FL**  
(Address of Principal Executive Offices)

**32708**  
(Zip Code)

**(407) 677-8022**

Edgar Filing: IRADIMED CORP - Form 8-K

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  X

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  X

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

(a) (b) The 2018 Annual Meeting of Stockholders of IRADIMED CORPORATION ( IRADIMED ) was held on Friday, June 8, 2018.

The final results of voting on each of the matters submitted to a vote of stockholders at the 2018 Annual Meeting are as follows:

1. Stockholders elected each of Roger Susi, Monty Allen, Anthony Vuoto and Jonathan Kennedy to IRADIMED s Board of Directors, each to hold office until succeeding annual meeting of stockholders or until such director s successor shall have been duly elected and qualified (or, if earlier, such director s removal or resignation from our Board), as set forth below.

<b>Name</b>	<b>Votes For</b>	<b>Votes Withheld</b>	<b>Broker Non-Votes</b>
Roger Susi	7,367,178	749,892	2,054,869
Monty Allen	7,374,408	742,662	2,054,869
Anthony Vuoto	7,339,631	777,439	2,054,869
Jonathan Kennedy	7,382,900	734,170	2,054,869

2. Stockholders ratified the selection of RSM US LLP as IRADIMED s independent registered public accounting firm to perform independent audit services for the fiscal year ending December 31, 2018, as set forth below.

<b>Votes For</b>	<b>Votes Against</b>	<b>Abstentions</b>
10,108,482	19,188	44,269

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IRADIMED CORPORATION**

Date: June 11, 2018

By:	/s/Chris Scott
Name:	Chris Scott
Title:	Chief Financial Officer